About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« USPTO News Briefs | Main | FDA Biosimilar Approval Recap – 2021 »

January 04, 2022

Comments

Looking in from Europe, I hope this split Decision will stimulate much debate about the WD requirement under First to File. There are nearly 50 members of this one patent family but, as yet, no patent issued by the EPO. Applicant is now on its third generation divisional there, unable to satisfy the EPC's WD requirements. Kevin, I looked for, but didn't find, in the above any opinion from you who has the better view, O'Malley or the Chief Judge.

Prosecution at the EPO in this case is enriched by numerous third party observations on patentability. Under FtF, rival filers slug it out on the exclusive basis of what each disclosed to the PTO, and on what date. The WD requirement is of decisive importance to the outcome. And then there are the ultra-high value evergreening cases too. It is inevitable that in the USA WD requirements will become progressively more onerous. Uncertain though, is how long it will take, to adjust to the exigencies of FtF patent law. See, it took the EPO decades to develop its notoriously strict "Gold Standard".

Thanks for the European perspective, Max, and Happy New Year.

You are correct that I did not opine on which opinion was best; I think Judges O'Malley and Moore set out the pros and cons of their positions very well, and believe it depends very much on what end of the telescope provides your perspective. If I had to choose I think Judge O'Malley's view is more flexible and capable of being applied more evenhandedly; the Chief Judge's position is very doctrinaire and rigid (which would nor fare well with our Supreme Court if they ever considered it which they won't; the issues are much to fact specific). And I also think that if the Chief believed this case smacked of the purported shenanigans associated with the Biogen v Mylan case that this likely colored her view.

The comments to this entry are closed.

May 2022

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31